• Publications
  • Influence
Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Background CD19‐specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B‐cell acute lymphoblastic leukemia (ALL) and long‐term remissionsExpand
  • 773
  • 32
The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts.
Interferons initiate the host antiviral response by inducing a number of genes, most with no defined antiviral function. Here we show that the interferon-induced protein viperin inhibits influenza AExpand
  • 380
  • 25
  • PDF
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: The role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential
The NS1 protein of influenza A virus contributes to viral pathogenesis, primarily by enabling the virus to disarm the host cell type IFN defense system. We examined the downstream effects of NS1Expand
  • 373
  • 19
The Ebola virus VP35 protein functions as a type I IFN antagonist.
An assay has been developed that allows the identification of molecules that function as type I IFN antagonists. Using this assay, we have identified an Ebola virus-encoded inhibitor of the type IExpand
  • 437
  • 16
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
CD19-specific chimeric antigen receptor (CAR) T-cell therapy is highly effective against relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity. In 53 adultExpand
  • 197
  • 16
Human Cytomegalovirus Up-Regulates the Phosphatidylinositol 3-Kinase (PI3-K) Pathway: Inhibition of PI3-K Activity Inhibits Viral Replication and Virus-Induced Signaling
ABSTRACT Infection of quiescent fibroblasts with human cytomegalovirus (HCMV) was found to cause a rapid activation of cellular phosphatidylinositol 3-kinase (PI3-K). Maximum PI3-K activationExpand
  • 223
  • 14
The Influenza A Virus NS1 Protein Inhibits Activation of Jun N-Terminal Kinase and AP-1 Transcription Factors
ABSTRACT The influenza A virus nonstructural NS1 protein is known to modulate host cell gene expression and to inhibit double-stranded RNA (dsRNA)-mediated antiviral responses. Here we identify NS1Expand
  • 183
  • 9
Clinical manufacturing of CAR T cells: foundation of a promising therapy
The treatment of cancer patients with autologous T cells expressing a chimeric antigen receptor (CAR) is one of the most promising adoptive cellular therapy approaches. Reproducible manufacturing ofExpand
  • 216
  • 7
Functional Replacement of the Carboxy-Terminal Two-Thirds of the Influenza A Virus NS1 Protein with Short Heterologous Dimerization Domains
ABSTRACT The NS1 protein of influenza A/WSN/33 virus is a 230-amino-acid-long protein which functions as an interferon alpha/beta (IFN-α/β) antagonist by preventing the synthesis of IFN during viralExpand
  • 114
  • 4
Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor
The successful genetic engineering of patient T cells with &ggr;-retroviral vectors expressing chimeric antigen receptors or T-cell receptors for phase II clinical trials and beyond requires theExpand
  • 42
  • 4